FMC63, binding to the paradigm CAR-target CD19, represents the best established and investigated scFv in CAR-T cell therapy, while B cell maturation antigen (BCMA) targeted via scFv BCMA30, is the most intensively-studied target in cellular immunotherapy of multiple myeloma (MM). Here, CD19 is linked to AL amyloidosis.